Startling Fact: PSA Testing Frequency Changes PSA Doubling Time – A Time Honored Surrogate Biomarker is Not Valid!

In our quest to understand our prostate cancer we have developed many “measures” of our disease aggressiveness and progression.  Many of these measures are generally accepted has valid, but many have never been validated. One example is the prognostic nature of PSA Doubling Time (PSADT) in men with biochemically recurrent prostate cancer (BRPC or PSA [...]

Oligometastatic Prostate Cancer – Still Curable So Be Vigilant

It is generally agreed that prostate cancer which is still 100% confined to the prostate gland is curable using local therapies like radiation or surgery, but when it has left the prostate gland and becomes metastatic it is no longer curable. Treatment for metastatic prostate cancer is intended to make the prostate cancer a chronic [...]

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

Study Shows that the Metastasis-Free Period Affects Prostate Cancer Patient Survival

A study from Michael T. Schweizer, MD, and colleagues at Johns Hopkins University in Baltimore Md. concluded that the longer the metastasis-free survival after a radical prostatectomy the longer overall survival in men who experience biochemical recurrence (PSA only recurrence) of their prostate cancer. This conclusion was made from a retrospectively study of 450 men [...]

Worthy New Immunotherapy Clinical Trial Opens at Johns Hopkins University for Men Thinking of Surgery

The exciting thing about Provenge is not only the real survival advantage that it offers with minimal side effects, but that it is a proof of concept treatment that is heralding in the potential future of many other immunotherapies. Today, we have two new possible treatments in active phase 3 trials, Prostvac and Yervoy. [...]

Go to Top